Search clinical trials for: AADvac1

Total 6 results

Axon Neuroscience SE

Unknown

A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (AIDA)

Primary Progressive Nonfluent Aphasia

Germany
Axon Neuroscience SE

Completed

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT)

Alzheimer's Disease

Poland, Austria, Czechia, Germany, Romania, Slovakia, Slovenia, Sweden
Axon Neuroscience SE

Completed

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Alzheimer Disease

Austria
Axon Neuroscience SE

Completed

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (FUNDAMANT)

Alzheimer's Disease

Austria
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute; Flinders University

Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (FLU003)

Influenza

Australia
Immatics Biotechnologies GmbH
BioNTech SE; University Hospital Tuebingen; BCN Peptides; EU-funded GAPVAC Consortium

Completed

GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

Glioblastoma

Spain, Switzerland, Denmark, Germany, Netherlands

3

Subscribe